Estrogen receptor α (ERα) and estrogen receptor β (ERβ) play important roles in
cardiovascular disease (CVD) prevention. Recently, these estrogen receptors were …

It has been reported that 17β-estradiol (E2) can exert beneficial effects against the
development of obesity, providing women with a healthier metabolic profile and conferring …

Abstract Objectives Type 2 diabetes (T2D) is a major risk factor for cardiovascular disorders
(CVD), characterized by pathological diastolic as well as systolic dysfunction, ventricular …

Estrogen is atheroprotective and a high-affinity ligand for both known estrogen receptors,
ERα and ERβ. However, the role of the ERα in early-stage atherosclerosis has not been …

Estrogen has an anti-obesity effect and plays an important role in improving cardiometabolic
disorders. Weight loss and reduction in calorie intake impede the development of obesity …

Obesity and menopause lead to cardiovascular diseases. Calorie restriction (CR) can
modulate estrogen deficiency and obesity-related cardiovascular diseases. The protective …

Menopause is associated with dyslipidemia and an increased risk of cardiovascular
disease, the underlying mechanism of dyslipidemia is attributed to an insufficiency of …

Background Estrogen was reported to protect against obesity, however the mechanism
remains unclear. We aimed to investigate the impact of 17β-estradiol (17β-E2) on …

The aim of this study was to investigate the in vivo effects of 17β-estradiol (E 2) on
myocardial metabolism and inducible nitric oxide synthase (iNOS) expression/activity in …

Objective: Cardiac mass increases with age and with declining estradiol serum levels in
postmenopausal women. Although the non-selective estrogen receptor-α and-β agonist 17β …